Consensus or Controversy, Issue 4: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Gastric Cancer
Faculty Comments on Anti-Angiogenesis in Gastric Cancer
In light of the AVAGAST trial data, do you expect that bevacizumab and newer-generation anti-angiogenic agents, such as ramucirumab, will play a significant role in the treatment of metastatic gastric cancer?
Consensus or Controversy, Issue 4: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Gastric Cancer
Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Bone-Directed Treatment in Prostate Cancer
Select review papers on hepatocellular carcinoma
Select review papers on hepatocellular carcinoma
El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365(12):1118-27. Abstract
Kim R et al. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park) 2011;25(3):283-91, 295. Abstract
Van Malenstein H et al. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer 2011;47(12):1789-97. Abstract
Two interesting reports on outcomes for patients with HCC who received liver transplants
Two interesting reports on outcomes for patients with HCC who received liver transplants
Åberg F et al. Long-term results of liver transplantation. Scand J Surg 2011;100(1):14-21. Abstract
Masuoka HC, Rosen CB. Liver transplantation for hepatocellular carnicoma: Expanding frontiers and building bridges. Clin Liver Dis 2011;15(2):385-93. Abstract
Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Hepatocellular Carcinoma
 |
 |
|
 |
||
Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Hepatocellular Carcinoma
Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Early HER2-Negative Breast Cancer and Triple-Negative Breast Cancer (TNBC)
 |
|||||
 |
|||||
Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Early HER2-Negative Breast Cancer and Triple-Negative Breast Cancer (TNBC)
Email from the Editor
Click here to go directly to the web- and video-based education resources related to this week’s topic
Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Early HER2-Negative Breast Cancer and Triple-Negative Breast Cancer (TNBC)
Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Early HER2-Negative Breast Cancer and Triple-Negative Breast Cancer (TNBC)
Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Metastatic HER2-Negative Breast Cancer and Triple-Negative Breast Cancer (TNBC)
|
|||||
|
|||||
Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Metastatic HER2-Negative Breast Cancer and Triple-Negative Breast Cancer (TNBC)
Email from the Editor
Click here to go directly to the web- and video-based education resources related to this week’s topic
Consensus or Controversy, Issue 1: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of HER2-Positive Breast Cancer
|
|||||
|
|||||
Consensus or Controversy, Issue 1: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of HER2-Positive Breast Cancer
Email from the Editor
Click here to go directly to the web- and video-based education resources related to this week’s topic